Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.

Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y.

Oncotarget. 2016 Jan 20. doi: 10.18632/oncotarget.6960. [Epub ahead of print]

2.

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MV, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP.

Cancer Cell. 2015 Dec 14;28(6):773-84. doi: 10.1016/j.ccell.2015.11.006.

PMID:
26678339
3.

Recurrent inactivating RASA2 mutations in melanoma.

Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y.

Nat Genet. 2015 Dec;47(12):1408-10. doi: 10.1038/ng.3427. Epub 2015 Oct 26.

PMID:
26502337
4.

The functional relevance of somatic synonymous mutations in melanoma and other cancers.

Gotea V, Gartner JJ, Qutob N, Elnitski L, Samuels Y.

Pigment Cell Melanoma Res. 2015 Nov;28(6):673-84. doi: 10.1111/pcmr.12413. Review.

PMID:
26300548
5.

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA.

Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28.

6.

YAP and the drug resistance highway.

Keren-Paz A, Emmanuel R, Samuels Y.

Nat Genet. 2015 Mar;47(3):193-4. doi: 10.1038/ng.3228.

PMID:
25711863
7.

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.

Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, Gutkind JS.

Oncotarget. 2014 Oct 15;5(19):8906-23.

8.

Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.

Walia V, Prickett TD, Kim JS, Gartner JJ, Lin JC, Zhou M, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y.

Hum Mutat. 2014 Nov;35(11):1301-10. doi: 10.1002/humu.22630. Epub 2014 Sep 10.

9.

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.

Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.

10.

A highly recurrent RPS27 5'UTR mutation in melanoma.

Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y.

Oncotarget. 2014 May 30;5(10):2912-7.

11.

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.

Prickett TD, Zerlanko BJ, Hill VK, Gartner JJ, Qutob N, Jiang J, Simaan M, Wunderlich J, Gutkind JS, Rosenberg SA, Samuels Y.

J Invest Dermatol. 2014 Sep;134(9):2390-8. doi: 10.1038/jid.2014.190. Epub 2014 Apr 16.

12.

ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

Lau C, Killian KJ, Samuels Y, Rudloff U.

Methods Mol Biol. 2014;1102:461-80. doi: 10.1007/978-1-62703-727-3_24.

PMID:
24258993
13.

Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.

Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J; NISC Comparative Sequencing Program, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y.

J Invest Dermatol. 2014 Feb;134(2):452-60. doi: 10.1038/jid.2013.365. Epub 2013 Sep 5.

14.

Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.

Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK; NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13481-6. doi: 10.1073/pnas.1304227110. Epub 2013 Jul 30. Erratum in: Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):563.

15.

The genetics of melanoma: recent advances.

Hill VK, Gartner JJ, Samuels Y, Goldstein AM.

Annu Rev Genomics Hum Genet. 2013;14:257-79. doi: 10.1146/annurev-genom-091212-153429. Epub 2013 Jul 12. Review.

PMID:
23875803
16.

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.

J Immunol. 2013 Jun 15;190(12):6034-42. doi: 10.4049/jimmunol.1202830. Epub 2013 May 20.

17.

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA.

Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.

18.

Shimmer: detection of genetic alterations in tumors using next-generation sequence data.

Hansen NF, Gartner JJ, Mei L, Samuels Y, Mullikin JC.

Bioinformatics. 2013 Jun 15;29(12):1498-503. doi: 10.1093/bioinformatics/btt183. Epub 2013 Apr 24.

19.

Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma.

Gartner JJ, Davis S, Wei X, Lin JC, Trivedi NS, Teer JK; NISC Comparative Sequencing Program, Meltzer PS, Rosenberg SA, Samuels Y.

BMC Genomics. 2012 Sep 24;13:505. doi: 10.1186/1471-2164-13-505.

20.

Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.

Parker SC, Gartner J, Cardenas-Navia I, Wei X, Ozel Abaan H, Ajay SS, Hansen NF, Song L, Bhanot UK, Killian JK, Gindin Y, Walker RL, Meltzer PS, Mullikin JC, Furey TS, Crawford GE, Rosenberg SA, Samuels Y, Margulies EH.

PLoS Genet. 2012;8(8):e1002871. doi: 10.1371/journal.pgen.1002871. Epub 2012 Aug 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk